Sector News

Medtronic to Acquire RF Surgical for $235 Million

July 15, 2015
Life sciences
Medtronic PLC agreed to acquire RF Surgical Systems Inc. for roughly $235 million, the latest in a string of smaller deals since the medical-device maker’s acquisition of Covidien.
 
Carlsbad, Calif.-based RF Surgical makes products that focus on counting items used during surgery—such as surgical sponges, gauze or towels—to help prevent them from being left in the patient during surgery, which can lead to serious complications.
 
RF Surgical’s system uses a low radio frequency signal to track and detect surgical gauze, sponges and towels, which are embedded with an RF tag, through blood, dense tissue and bone.
 
The deal, expected to close next month, is expected to meet Medtronic’s long-term financial metrics for acquisitions, though the deal’s effect on yearly earnings isn’t expected to be material.
 
Medtronic last month agreed to acquire privately held medical-device company Aptus Endosystems Inc. for roughly $110 million and cardiac-mapping company CardioInsight Technologies Inc. in a deal valued at $93 million.
 
Also in June, Medtronic reported a net loss of $1 million in its first combined quarter with Covidien, largely because of $880 million in charges for the Covidien acquisition and a $329 million expense from the resolution of a tax dispute with the Internal Revenue Service.
 
By Tess Stynes
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”